Results
Dr. Reddy's Q1 Profit Drops on Semaglutide Provision
Dr. Reddy's Q1 FY27 revenue declined 5.6% YoY to ₹8,071 Cr, with EBITDA margin at 12.5%, impacted by a ₹240 Cr provision for semaglutide API issues.
The underlying base business, excluding lenalidomid
